NEW YORK (GenomeWeb News) – The Prostate Cancer Foundation is granting several million dollars through its Challenge Awards to three research programs that will use genomics-based projects in the effort to discover new treatments for recurrent prostate cancer.
Under the $19 million total funding the PCF said this week that it plans to grant to eight research groups, the organization will give between $500,000 and $1 million this week to scientists studying progression biomarkers, epigenetics, and molecular analysis for immunotherapy. These payments will be the first of three that PCF will spread over three years.
Massachusetts General Hospital’s research group will receive an award for biomarker-related studies that can help in analyzing the progression of prostate cancer.
The University of California, San Diego will use an award to study the epigenetic and genetic changes that result in prostate cancer.
PCF also is giving an award to Memorial Sloan Kettering Cancer Center to perform molecular analysis of patient response to immunotherapy for prostate cancer treatment.